Reclaimed at end of life
Tonnes as filed. Totals combine re-used, recycled and safely disposed, because filers place comparable activity in different columns.
| Category | FY 2025-26 |
|---|---|
| Plastics including packaging | 30.88 |
| E-waste | 2.74 |
| Hazardous waste | 13,593.43 |
| Other waste | not filed |
| Total reclaimed | 13,627.05 |
Recycled or reused input material
Share of total material by value, per material line as the company named it. Each line carries its own denominator, so they are never summed or averaged.
| Input material, as filed | FY 2025-26 |
|---|---|
| As a pharmaceutical manufacturer, only fresh pharmaceutical-grade input materials are used for APIs and formulations; use of recycled/reused materials is not feasible. | 0.0% |
NIC codes filed
Products and services accounting for 90 percent of turnover, latest filing.
| Code | Description as filed | Share of turnover |
|---|---|---|
| 21001 | Linezolid (Human API - Antibiotic) | 14.49% |
| 21001 | Albendazole (Animal health API - Anthelmintic) | 14.25% |
| 21001 | Triclabendazole (Animal health API - Anthelmintic) | 5.19% |
| 21001 | Tapentadol HCl (Human API - Analgesic) | 4.76% |
| 21001 | Hydroxyzine HCl (Human API - Antihistamine) | 4.46% |
| 21001 | Levocetirizine (Human API - Antihistamine) | 4.24% |
| 21001 | Others | 52.61% |
Source filings
| Year | Basis | Taxonomy | Turnover as filed |
|---|---|---|---|
| FY 2025-26 | Consolidated | 2026-02-28 | 18,31,51,00,000 |
Figures read from BRSR XBRL as filed. Nothing estimated or restated. How this works · Report an error